Martin Hutchings, Anna Sureda Balarí, Francesc Bosch Albareda, Thomas Larsen, Paolo Corradini, Abraham Avigdor, Maria Jose Terol, Antonio Rueda Dominguez, Antonio Pinto, Alan Skarbnik, Raúl Córdoba, Judit Jørgensen, Pier Luigi Zinzani, Ronit Gurion, Neta Goldschmidt, Wilfred Leung, Donghang Li, James Relf, Martine Joanna Kallemeijn, Gila Sellam, Giuseppe Gritti. "Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis." Blood, 2025. doi:10.1182/blood-2025-5510